An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications worldwide.
VERDICT
The label
Markup
read at $157.51
ICU Medical, Inc. holds its Markup at $157.51.
PHPhase · the trend structure carries the Markup label
INInsiders · no filings inside 60 days, left as found
POPositioning · no disclosures inside 60 days, left as found
OPOptions · no verdict drawn today, left as found
SCScreen · passes the values gate
edge confirmed
edge broken
edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
INVESTOR
The investor read · the season, not the day
As held on the ledger · 2025-12-31
Phase
Markup
Quantitative state
Elevated stress, defensive posture warranted, held for 181 days
Price
$157.51
Valuation
84.68 trailing · 16.87 forward price to earnings
Values screen
PASS· score 70.0
Beta
0.76
OPPORTUNITY
The opportunity · what the numbers say it is worth
Read at
$157.51
84.68 P/E · 16.87 fwd
Our fair value
$188.94
20% discount
Analyst target (avg)
$172.50
+10% to current
Target low $163.00Analyst target rangeTarget high $200.00
▲ current $157.51 · | average target
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Current
$157.51
you are here
Conservative
$154.03
-2%
Analyst avg
$172.50
+10%
Our fair value
$188.94
+20%
Analyst high
$200.00
+27%
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Revenue growth
-12.30%
Profit margin
2.15%
Debt to equity
63.62
Analyst consensus
Buy · 8 covering
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
SCREEN
The values screen, explained · five checks, plain English
It depends which standard you follow. There are two widely recognised ways to check whether a company is suitable for a Muslim investor, and on this company they disagree. Here is how it did on each:
The common standard· AAOIFI Used by most halal investing apps✗ DOES NOT PASS
Our stricter standard· asset-based The one Titan applies✓ PASSES
Why the two disagree. They fall out over one thing only: the company’s debt. Our stricter standard measures that debt against what the company owns, and it works out too high to pass. The common standard measures the same debt against what the company is worth on the stock market, where it works out low enough to pass. Every other check, the two agree on. So in practice, most halal apps would treat this as fine to hold, while our stricter view would not — and which line you follow is between you and your scholar.
Business activityIts core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending.Pass
Debt loadInterest-bearing debt is just 32.9% of its assets, well under the one-third ceiling — it does not run on borrowed money. Against market value it is 34.1%, under the 30% line the market-value standard uses — so that standard clears it.Divergent
Interest-bearing cashCash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.Pass
ReceivablesMoney owed to the company is 12.1% of assets, under the 49% limit.Pass
Revenue purityOnly 0.5% of revenue comes from non-compliant sources — under the 5% line.Pass
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
PLAIN
The business, in plain words · what the numbers mean
Infusion Products Maker Struggles With Shrinking Demand
Picture a hospital ward where every drip line and connector once drove steady orders. ICU Medical now faces the opposite, with revenue down 12 percent and both profit margin and return on equity stuck at just 2 percent. The shares sit below our fair value estimate, yet the opportunity rating stays at none because the underlying numbers show no durable improvement.
The business makes essential needlefree connectors and infusion sets that hospitals rely on every day. A forward multiple of 16.9 times earnings looks reasonable on the surface and the ethical screen clears without issue. Eight analysts still lean buy with a median target of 172 dollars, but those forecasts sit against a backdrop of flat or falling volumes rather than renewed growth.
Risk centres on whether the recent revenue drop proves temporary or signals lasting pressure on hospital spending and product pricing. Low returns on equity already flag limited ability to compound capital, and an unknown competitive position leaves little margin for error if larger rivals push harder. Analysis, not advice.
Screened names in the same industry · explore each on its own page.
TRADE
Where & how to trade · wherever in the world you are
ICUI trades on Nasdaq. As a US-listed security it is accessible through almost any international broker offering US markets. New to this, or investing from outside the US? Our guide to accessing global markets covers brokers, currencies and the practical steps.
TRADER
The trader read · the latest dated commentary
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 10.8% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 3%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (7 analysts) rates it buy, with a mean price target of $173. Entered 2026-08-02 · Markup
JOURNAL
The dated journal · newest first, never edited
2026-08-02Markup$157.51+10.8%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 10.8% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 3%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (7 analysts) rates it buy, with a mean price target of $173.
2026-07-18Markup$142.20+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 3%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (7 analysts) rates it buy, with a mean price target of $173.
2026-07-03Markup$142.20+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Markup$142.20Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
RETURNS
What holding actually paid · price plus dividends
If $1,000 had been placed · historical, not a promise
Period
Price then
Price return
Divs per share
$1,000 became
Total return
1 month
$124.68
+13.0%
·
$1,130
+13.0%
2 months
$125.68
+12.1%
·
$1,121
+12.1%
3 months
$128.78
+9.4%
·
$1,094
+9.4%
6 months
$147.22
-4.3%
·
$957
-4.3%
1 year
$136.79
+3.0%
·
$1,030
+3.0%
2 years
$110.66
+27.4%
·
$1,274
+27.4%
3 years
$188.80
-25.4%
·
$746
-25.4%
5 years
$204.90
-31.2%
·
$688
-31.2%
Historical returns from market close data. Past performance does not guarantee future results.
SEALED
This entry now belongs to the ledger. Whatever ICUI does next, these words stay.
ICU Medical, Inc. · ICUI · Markup · $157.51
Recorded 2025-12-31 · before the outcome · scored mechanically
